Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?

Abstract:

:Follicular lymphoma (FL), the most common subtype of indolent lymphoma, is usually diagnosed at an advanced stage (III-IV), although patients are often asymptomatic. Traditionally, a palliative approach to management has been taken, cycling through watchful waiting, radiotherapy, oral alkylating agents and, eventually, combination chemotherapy, as deemed necessary. However, accumulating evidence suggests that in patients requiring treatment, early initiation of an anthracycline-based regimen may achieve better response rates and progression-free survival compared with reserving such options until late in the course of disease. Delivery of myelosuppressive chemotherapy has been facilitated by the availability of granulocyte colony-stimulating factors. Incorporation of the anti-CD20 monoclonal antibody rituximab into upfront chemotherapy regimens further improves outcomes. With a trend towards early use of rituximab chemotherapy combinations, median survival appears to have increased in patients with FL. A number of issues remain to be addressed by ongoing research. These include identification of the most effective rituximab chemotherapy regimen, the impact of treatment on responsiveness to future treatment, the need for rituximab maintenance therapy and the place of newer treatments. Clearly, there are arguments in favour of considering early aggressive rituximab and chemotherapy regimens in patients with FL requiring treatment, and it is hoped that new prognostic tools will help us to more accurately identify which patients are most likely to benefit.

journal_name

Drugs

journal_title

Drugs

authors

Pettengell R

doi

10.2165/11317050-000000000-00000

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

1727-37

issue

13

eissn

0012-6667

issn

1179-1950

pii

1

journal_volume

69

pub_type

杂志文章

相关文献

DRUGS文献大全
  • Antiarrhythmic therapies for the prevention of sudden cardiac death.

    abstract::Despite remarkable advances in cardiovascular therapeutics, sudden cardiac death remains a significant problem. In this review, data from clinical trials and other studies on antiarrhythmic therapies have been evaluated in order to determine effective strategies for the prevention of sudden cardiac death in high risk ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754020-00003

    authors: McAlister FA,Teo KK

    更新日期:1997-08-01 00:00:00

  • The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0565-4

    authors: Seiler T,Hutter G,Dreyling M

    更新日期:2016-04-01 00:00:00

  • Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines.

    abstract::During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958003-00016

    authors: Diasio RB

    更新日期:1999-01-01 00:00:00

  • Suvorexant: first global approval.

    abstract::Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0294-5

    authors: Yang LP

    更新日期:2014-10-01 00:00:00

  • Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

    abstract::The oral deoxyguanosine nucleoside analogue entecavir (Baraclude®) has potent activity against hepatitis B virus (HBV) and a high genetic barrier to resistance. This article reviews the clinical efficacy and tolerability of entecavir in the treatment of chronic hepatitis B in patients with decompensated liver disease,...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208510-000000000-00000

    authors: Keating GM

    更新日期:2011-12-24 00:00:00

  • Heparin Therapy: regimens and management.

    abstract::Heparin remains the most effective antithrombotic drug. It acts by combining with plasma antithrombin, thereby accelerating the neurtalisation of thrombin and other acitvated coagulation factors. Full-dose intravenous heparin is indicated in all cases of pulmonary embolism and established deep venous thrombosis, unles...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197713010-00005

    authors: Deykin D

    更新日期:1977-01-01 00:00:00

  • The sore throat. When to investigate and when to prescribe.

    abstract::Sore throats are most commonly due to infections, many of which are viral and do not require specific treatment. Symptoms and signs of the common cold, influenza or croup, the occurrence of conjunctivitis in some adenoviral infections, generalised lymphadenopathy and splenomegaly in glandular fever or the presence of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040060-00007

    authors: Lang SD,Singh K

    更新日期:1990-12-01 00:00:00

  • Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

    abstract::Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more fre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969060-00004

    authors: Patel M

    更新日期:2009-01-01 00:00:00

  • Are All Dopamine Agonists Essentially the Same?

    abstract::Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01103-2

    authors: Torti M,Bravi D,Vacca L,Stocchi F

    更新日期:2019-05-01 00:00:00

  • Quinolone activity against anaerobes: microbiological aspects.

    abstract::Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxa...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00012

    authors: Appelbaum PC

    更新日期:1995-01-01 00:00:00

  • Anagrelide: a review of its use in the management of essential thrombocythaemia.

    abstract::Anagrelide (Agrylin, Xagrid) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of elevated platelet counts and t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666010-00006

    authors: Wagstaff AJ,Keating GM

    更新日期:2006-01-01 00:00:00

  • Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::Flecainide is a Class I antiarrhythmic drug of the local anaesthetic type. It can be given either intravenously or orally and its pharmacokinetic properties allow relatively long (12 hours) dosing intervals with oral administration. In several open and a few controlled therapeutic trials, orally administered flecainid...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529010-00001

    authors: Holmes B,Heel RC

    更新日期:1985-01-01 00:00:00

  • Epidemiological considerations in the treatment of hypertension.

    abstract::Cardiovascular disease continues to be the principal cause of death in Western countries. Epidemiological studies have repeatedly demonstrated a striking relationship between blood pressure and the risk of cardiovascular disease in that those with the highest levels of blood pressure are at the greatest risk for subse...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600314-00003

    authors: Whelton PK,Klag MJ

    更新日期:1986-01-01 00:00:00

  • Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?

    abstract::Janus kinase (JAK) is a signal transducer and activator of a protein transcription system that transduces signals from cell surface cytokine and growth factor receptors to the nucleus. Recently developed JAK inhibitors (JAKinibs) inhibit JAKs non-selectively or selectively and down-regulate the effects of correspondin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01349-1

    authors: Harigai M,Honda S

    更新日期:2020-08-01 00:00:00

  • The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological and clinical gastrointestinal effects.

    abstract::Metabolites of arachidonic acid have a broad range of physiological functions in the gastrointestinal tract, and seem to be involved in certain disturbances of gastrointestinal integrity and function. Prostaglandins inhibit gastric acid secretion, apparently via an adenylate cyclase-linked receptor, and also stimulate...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198700331-00007

    authors: Isselbacher KJ

    更新日期:1987-01-01 00:00:00

  • Phentermine and topiramate extended release (Qsymia™): first global approval.

    abstract::Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight los...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11640860-000000000-00000

    authors: Cameron F,Whiteside G,McKeage K

    更新日期:2012-10-22 00:00:00

  • Sickle cell disease in children.

    abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11632890-000000000-00000

    authors: Meier ER,Miller JL

    更新日期:2012-05-07 00:00:00

  • Eravacycline: A Review in Complicated Intra-Abdominal Infections.

    abstract::Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01067-3

    authors: Scott LJ

    更新日期:2019-02-01 00:00:00

  • Chemotherapy in the management of bladder tumours.

    abstract::For patients with superficial bladder tumours intravesical treatment or prophylaxis with thiotepa, doxorubicin, mitomycin C or Bacillus Calmette-Guerin has added a useful dimension to management, although the precise indications for each regimen remain to be better defined. For patients with metastatic bladder cancer ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198938020-00009

    authors: Whitmore WF Jr,Yagoda A

    更新日期:1989-08-01 00:00:00

  • Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women.

    abstract::For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666170-00001

    authors: Mitwally MF,Casper RF

    更新日期:2006-01-01 00:00:00

  • MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

    abstract::MenB-FHbp (bivalent rLP2086; Trumenba®) is a recombinant protein-based vaccine targeting Neisseria meningitidis serogroup B (MenB), which has recently been licensed in the EU for active immunization to prevent invasive disease caused by MenB in individuals ≥ 10 years of age. The vaccine, which contains a variant from ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0869-7

    authors: Shirley M,Taha MK

    更新日期:2018-02-01 00:00:00

  • Hepatitis E vaccines: progress and prospects.

    abstract::Hepatitis E accounts for the major part of enterally transmitted non-A, non-B hepatitis worldwide. Its agent, the hepatitis E virus (HEV), is a small, single-stranded RNA virus. Only one serotype of HEV is recognised. Infection results in protective immunity with long-lived neutralising antibodies. In developing count...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464140-00002

    authors: Worm HC,Wirnsberger G

    更新日期:2004-01-01 00:00:00

  • Antibiotics in neonatal infections: a review.

    abstract::The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, es...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958030-00003

    authors: Fanos V,Dall'Agnola A

    更新日期:1999-09-01 00:00:00

  • Postmenopausal hormone replacement therapy and cardiovascular risk reduction. A review.

    abstract::Administration of unopposed postmenopausal estrogen therapy protects against coronary heart disease (CHD) in women. This is mediated, in part, through beneficial effects on lipid and lipoprotein metabolism. Fewer data are available with regard to CHD risk reduction when a progesterone is required in addition to estrog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400472-00005

    authors: Kafonek SD

    更新日期:1994-01-01 00:00:00

  • Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::The clonidine transdermal therapeutic system (TTS) is a cutaneous delivery device which provides therapeutically effective doses of clonidine at a constant rate over 7 days. In clinical trials it reduces blood pressure in patients with mild to moderate hypertension as effectively as oral clonidine but with greater sta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835020-00003

    authors: Langley MS,Heel RC

    更新日期:1988-02-01 00:00:00

  • Antiplatelet drugs: clinical pharmacology and therapeutic use.

    abstract::Because platelets are so important in thrombus formation, drugs which inhibit platelet function (the 'antiplatelet drugs') have considerable potential as antithrombotic agents. Among the antiplatelet drugs, only aspirin, sulphinpyrazone, dipyridamole, hydroxychloroquine, and clofibrate have had wide clinical trial. Th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197918060-00002

    authors: Gallus AS

    更新日期:1979-12-01 00:00:00

  • Clascoterone: First Approval.

    abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01417-6

    authors: Dhillon S

    更新日期:2020-11-01 00:00:00

  • Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.

    abstract::The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199200441-00002

    authors: Fuenmayor NT,Faggin BM,Cubeddu LX

    更新日期:1992-01-01 00:00:00

  • [Pain management: health economics and quality of life considerations].

    abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Phillips CJ

    更新日期:2003-01-01 00:00:00

  • Lumasiran: First Approval.

    abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01463-0

    authors: Scott LJ,Keam SJ

    更新日期:2021-01-06 00:00:00